Strensiq

Ingredient

Asfotase-alfa

Content

18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or 80 mg/0.8 mL solution in single-dose vials

Indication

Long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease. Pediatric includes perinatal/infantile (0-6 months of age at the time of onset) and juvenile (6 months to 18 years of age at the time of onset).